Fresh Tracks Therapeutics (NASDAQ:FRTX) & Black Diamond Therapeutics (NASDAQ:BDTX) Head-To-Head Review

Black Diamond Therapeutics (NASDAQ:BDTX) and Fresh Tracks Therapeutics (NASDAQ:FRTX) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, earnings, profitability, institutional ownership, dividends and analyst recommendations.

Analyst Ratings

This is a summary of current ratings for Black Diamond Therapeutics and Fresh Tracks Therapeutics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Black Diamond Therapeutics	0	0	5	0	3.00
Fresh Tracks Therapeutics	0	0	0	0	0.00

Black Diamond Therapeutics currently has a consensus price target of $14.60, indicating a potential upside of 554.71%. Given Black Diamond Therapeutics’ stronger consensus rating and higher probable upside, research analysts plainly believe Black Diamond Therapeutics is more favorable than Fresh Tracks Therapeutics.

Insider and Institutional Ownership

95.5% of Black Diamond Therapeutics shares are held by institutional investors. Comparatively, 25.0% of Fresh Tracks Therapeutics shares are held by institutional investors. 8.9% of Black Diamond Therapeutics shares are held by company insiders. Comparatively, 0.2% of Fresh Tracks Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Earnings and Valuation

This table compares Black Diamond Therapeutics and Fresh Tracks Therapeutics”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Black Diamond Therapeutics	$70.00 million	1.81	-$82.44 million	$0.06	37.17
Fresh Tracks Therapeutics	$10.06 million	0.56	-$5.69 million	($1.41)	-0.66

Fresh Tracks Therapeutics has lower revenue, but higher earnings than Black Diamond Therapeutics. Fresh Tracks Therapeutics is trading at a lower price-to-earnings ratio than Black Diamond Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Black Diamond Therapeutics and Fresh Tracks Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Black Diamond Therapeutics	N/A	-68.08%	-49.65%
Fresh Tracks Therapeutics	N/A	N/A	N/A

Volatility and Risk

Black Diamond Therapeutics has a beta of 2.63, meaning that its share price is 163% more volatile than the S&P 500. Comparatively, Fresh Tracks Therapeutics has a beta of 0.54, meaning that its share price is 46% less volatile than the S&P 500.

Summary

Black Diamond Therapeutics beats Fresh Tracks Therapeutics on 9 of the 13 factors compared between the two stocks.

About Black Diamond Therapeutics

Black Diamond Therapeutics, Inc., a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma. It is also developing BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS, and BRAF alterations in solid tumors that is in phase 1 clinical trial. In addition, the company is developing BDTX-4876, a MasterKey inhibitor of oncogenic FGFR2/3 mutations with selectivity versus FGFR1/4, which is in preclinical stage. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

About Fresh Tracks Therapeutics

Fresh Tracks Therapeutics, Inc. does not have significant operations. Previously, the company was engaged in the development of various prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases in the United States. Fresh Tracks Therapeutics, Inc. was founded in 2009 and is headquartered in Boulder, Colorado.